By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    physical health
    5 Ways Playing Games Can Improve Neural and Physical Health
    September 9, 2022
    Reasons For Hair Loss and Its Treatment
    Reasons For Hair Loss and Its Treatment
    February 16, 2022
    healthcare organization
    5 Actionable Strategies For Healthcare Organizations
    August 15, 2022
    Latest News
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    The Latest Numbers on Exchange Enrollment
    January 20, 2014
    conversational AI in healthcare
    How Conversational AI is Making Healthcare More Patient-Centric
    July 24, 2024
    create tracking metrics HIS
    Create Tracking Metrics for ICD-10 Preparation
    February 18, 2014
    Latest News
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
    Top HIPAA-Compliant Messaging Apps for Healthcare Teams
    June 25, 2025
    When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
    June 20, 2025
    Preventing Contamination In Healthcare Facilities Starts With Hygiene
    June 15, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: UM Spinoff Takes Rare Adrenal Cancer Drug to Clinical Trials
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > UM Spinoff Takes Rare Adrenal Cancer Drug to Clinical Trials
BusinessFinanceSpecialties

UM Spinoff Takes Rare Adrenal Cancer Drug to Clinical Trials

Deanna Pogorelc
Deanna Pogorelc
Share
5 Min Read
SHARE

First published on MedCityNews.com.

Raili KerppolaRaili Kerppola had a thriving career in the pharmaceutical industry when she was diagnosed with stage four adrenal cancer in 2011. 

First published on MedCityNews.com.

Raili KerppolaRaili Kerppola had a thriving career in the pharmaceutical industry when she was diagnosed with stage four adrenal cancer in 2011. 

More Read

todd dunsirn
Interview with Todd Dunsirn of True Process
Physician Payments: The Not-So-Secret Secret
Reducing Surgical Complications – The Checklist
Top Benefits of Electronic Health Records for Psychiatrists and Psychologists
Socialcam: Mobile Video Sharing Made Easy

While seeking treatment at the University of Michigan, she began working with an endocrinologist named Dr. Gary Hammer and her husband, a professor of biological chemistry at UM, on researching and discovering new treatments for the rare disease.

Kerppola died this June. But her legacy lives on through a VC-backed company called Atterocor, for which she is credited as a co-founder. The University of Michigan spinoff is conducting a Phase 1 clinical study of a drug that it hopes could prolong the lives of patients with adrenocortical carcinoma, and cause fewer toxic side effects, than the current treatment option.

It’s a rare form of cancer that carries a short life expectancy after diagnosis.  That’s because it’s usually caught late-stage, when a patient presents with symptoms like unexplainable weight gain, hypertension, abdominal pain or other metabolic complications caused by excessive production of hormones by the adrenal glands.

Treatment starts with surgery, if the cancer is caught early enough. Then, doctors usually try to extend life with a cocktail of chemotherapy drugs including mitotane, a drug that reduces the amount of hormone produced by the adrenal cortex.

The problem? Mitotane, a derivative of the pesticide DDT, is terribly toxic. And its efficacy is questionable, too.  Atterocor co-founder Julia Owens said the FDA approved the drug decades ago, before the agency required drugmakers to demonstrate that it works before approval. She said that although it likely does have some benefits for patients, they usually have to take multiple doses a day for three to four months before their mitotane levels reach a therapeutic range. Meanwhile, they’re usually also taking chemotherapy drugs.

“One endocrinologist recently told me that the way you can tell if a patient is getting close to efficacious mitotane levels is when they can’t walk down the hallway without assistance,” she said.

Atterocor says its compound is highly specific to the cells of the adrenal cortex, which is where the cancer occurs. “We haven’t done human trials yet so we can’t make any claims, but based on toxicity studies, our effect seems much more specific, much more rapid, with a better (pharmacokinetic) profile,” she explained.

It’s received orphan drug designation in the U.S. and in Europe. The company started a Phase 1 trial over the summer at MD Anderson Cancer Center and the University of Michigan Comprehensive Cancer Center. Owens said the company should have some data on tumor responses and steroid markers in the next six to 12 months.

With six employees, Atterocor is a small company, but it’s attracted some big-name investors. Last year the Ann Arbor startup reined in a $16 million Series A from Frazier Healthcare, Osage University Partners and 5AM Ventures.

Owens said that, for a company developing an orphan drug, that capital makes all the difference. “We can move this compound forward ourselves without being at the mercy of a big pharma company (partner),” she said.  “We haven’t been around for two years yet and have taken this idea from the University of Michigan and run our toxicology studies, synthesize the drug and now are running the study. If we see encouraging results, we could go into a Phase 2 study and seek approval ourselves.”

You have to think that’s something Raili Kerppola would be proud of.

TAGGED:Atterocorcancerhealth start-ups!
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

car accident lawsuit
Let Your Lawyer Handle the Work Before You Pay Medical Costs
Policy & Law
July 6, 2025
women dental care
What Is a Smile Makeover and How Much Does It Cost?
Dental health
June 30, 2025
HIPAA-Compliant Messaging Apps
Top HIPAA-Compliant Messaging Apps for Healthcare Teams
Global Healthcare Policy & Law Technology
June 25, 2025
recovering from injury
Rebuilding After Injury: Path to Physical and Emotional Recovery
News
June 22, 2025

You Might also Like

physician reputation management
Business

10 Ways to Build a Better Physician Reputation

January 28, 2016
national healthcare decisions day
NewsSpecialties

6th Annual National Healthcare Decisions Day: April 16

March 2, 2013

Why Hospitals Need Content Management to Maximize Patient Experience

May 25, 2013
social media use for medical site
BusinesseHealthSocial MediaTechnology

How Social Media Can Boost Your Medical Site

June 9, 2017
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?